Your session is about to expire
← Back to Search
Phosphodiesterase 4 (PDE4) inhibitor
Psoriasis Patients on Comb. Treatment for Psoriasis
Phase 4
Waitlist Available
Research Sponsored by Washington Dermatology Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Study Summary
Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast is used by itself.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Psoriasis Area Severity Index (PASI)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Psoriasis Patients on Comb. TreatmentExperimental Treatment1 Intervention
Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
Find a Location
Who is running the clinical trial?
Washington Dermatology CenterLead Sponsor
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger